SEP-363856 mesylate  (Synonyms: SEP-856 mesylate)

SEP-363856 (SEP-856) mesylate, an orally active TAAR1 and 5-HT1A agonist and CNS active psychotropic agent with a unique, non-D2/5-HT2A mechanism of action, exerts its antipsychotic-like effects. SEP-363856 mesylate has the potential for the study of schizophrenia^[1].

SEP-856 (10 μM) mesylate shows >50% inhibition of specific binding at α_2A, α_2B, D₂, 5-HT_1A, 5-HT_1B, 5-HT_1D, 5-HT_2A, 5-HT_2B, 5-HT_2C, and 5-HT₇ receptors^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

SEP-856 (0.3, 1 and 10 mg/kg, i.p.) mesylate is CNS active and exhibits a behavioral signature similar to known antipsychotic drugs^[1].
SEP-856 (0.3, 1 and 10 mg/kg, orally once) mesylate significantly reduces PCP-induced hyperactivity^[1].
Oral SEP-856 mesylate administration (1, 3 and 10 mg/kg) produces a dosedependent decrease in REM sleep, increase in latency to REM sleep and increase in cumulative wake (W) time^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

279.38

C₁₀H₁₇NO₄S₂

2375116-27-9

CS(=O)(O)=O.CNC[C@H]1C2=C(CCO1)C=CS2

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Dedic N, et al. SEP-363856, a Novel Psychotropic Agent with a Unique, Non-D2 Receptor Mechanism of Action. J Pharmacol Exp Ther. 2019 Oct;371(1):1-14.  [Content Brief]